Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
Globus Medical (NYSE: GMED) has secured a favorable jury verdict in a patent infringement case against Life Spine, Inc. in Delaware. The jury found that Life Spine's Prolift implants infringed on Globus Medical's patent for expandable spinal fusion implants, awarding both lost profits and reasonable royalty damages.
The company, led by CEO Keith Pfeil, also has a separate ongoing patent litigation against Alphatec, Inc. regarding expandable implant and retractor technology. The verdict reinforces Globus Medical's position as a leading innovator in musculoskeletal technology, particularly in expandable implant technologies that improve spinal surgery outcomes.
Globus Medical (NYSE: GMED) ha ottenuto un verdetto favorevole da una giuria in una causa per violazione di brevetto contro Life Spine, Inc. nel Delaware. La giuria ha stabilito che gli impianti Prolift di Life Spine hanno violato il brevetto di Globus Medical relativo a impianti espandibili per la fusione spinale, riconoscendo sia i profitti perduti sia una royalty ragionevole come risarcimento.
L'azienda, guidata dall'amministratore delegato Keith Pfeil, è inoltre coinvolta in un'altra controversia brevettuale in corso contro Alphatec, Inc. relativa alla tecnologia di impianti espandibili e dei retrattori. Il verdetto rafforza la posizione di Globus Medical come innovatore di riferimento nella tecnologia muscoloscheletrica, in particolare nelle soluzioni di impianti espandibili che migliorano gli esiti della chirurgia spinale.
Globus Medical (NYSE: GMED) logró un veredicto favorable de un jurado en un caso por infracción de patente contra Life Spine, Inc. en Delaware. El jurado determinó que los implantes Prolift de Life Spine infringieron la patente de Globus Medical sobre implantes expansibles para la fusión espinal, concediendo tanto las ganancias perdidas como una indemnización por regalías razonables.
La compañía, dirigida por el CEO Keith Pfeil, también mantiene un litigio de patentes separado y en curso contra Alphatec, Inc. relacionado con tecnología de implantes expansibles y retractores. El veredicto refuerza la posición de Globus Medical como líder innovador en tecnología musculoesquelética, especialmente en tecnologías de implantes expansibles que mejoran los resultados de la cirugía de columna.
Globus Medical (NYSE: GMED)는 델라웨어에서 Life Spine, Inc.을 상대로 한 특허 침해 소송에서 배심원의 유리한 평결을 얻었습니다. 배심원단은 Life Spine의 Prolift 임플란트가 확장형 척추 유합 임플란트에 대한 Globus Medical의 특허를 침해했다고 판단해 상실 이익과 합리적인 로열티 손해배상을 인정했습니다.
Keith Pfeil CEO가 이끄는 이 회사는 확장형 임플란트 및 견인기(retractor) 기술과 관련해 Alphatec, Inc.를 상대로 한 별도의 진행 중인 특허 소송도 진행하고 있습니다. 이번 평결은 척추 수술 결과를 개선하는 확장형 임플란트 기술을 포함한 근골격계 기술 분야에서 Globus Medical의 선도적 혁신자 위치를 강화합니다.
Globus Medical (NYSE: GMED) a obtenu un verdict favorable d'un jury dans une affaire de contrefaçon de brevet contre Life Spine, Inc. dans le Delaware. Le jury a conclu que les implants Prolift de Life Spine enfreignaient le brevet de Globus Medical relatif aux implants expansibles pour fusion spinale, accordant à la fois des profits perdus et des dommages-intérêts sous forme de redevance raisonnable.
La société, dirigée par le PDG Keith Pfeil, est également engagée dans un autre litige en cours contre Alphatec, Inc. concernant la technologie des implants expansibles et des rétracteurs. Le verdict renforce la position de Globus Medical en tant qu'innovateur de premier plan dans la technologie musculosquelettique, en particulier pour les technologies d'implants expansibles qui améliorent les résultats des interventions sur la colonne vertébrale.
Globus Medical (NYSE: GMED) hat in Delaware ein günstiges Geschworenengerichtsurteil in einem Patentverletzungsverfahren gegen Life Spine, Inc. errungen. Die Jury befand, dass Life Spines Prolift-Implantate das Patent von Globus Medical für erweiterbare Wirbelsäulen-Fusionsimplantate verletzen und sprach sowohl entgangenen Gewinn als auch eine angemessene Lizenzvergütung zu.
Das Unternehmen unter der Leitung von CEO Keith Pfeil führt zudem ein separates, laufendes Patentverfahren gegen Alphatec, Inc. in Bezug auf erweiterbare Implantat- und Retraktor-Technologie. Das Urteil stärkt Globus Medicals Position als führender Innovator in der muskel-skelettalen Technologie, insbesondere bei erweiterbaren Implantat-Technologien, die die Ergebnisse von Wirbelsäulenoperationen verbessern.
- Favorable jury verdict confirming patent infringement by Life Spine
- Award of both lost profits and royalty damages
- Strong validation of company's intellectual property portfolio
- Protection of innovative expandable implant technology
- Ongoing litigation costs with pending Alphatec case
- Competitive pressure in the expandable implant market
Insights
Globus Medical's patent victory against Life Spine strengthens IP position and potentially increases market share in expandable implants.
Globus Medical's legal victory represents a significant reinforcement of their intellectual property portfolio in the competitive musculoskeletal technology space. The jury's finding that Life Spine's Prolift family infringed on Globus's expandable spinal fusion implant patent has several important implications.
The verdict includes both
More strategically valuable is the competitive market positioning this provides. Expandable spinal fusion implants represent an advanced segment of the spinal surgery market with likely premium pricing and margins. By successfully defending this technology, Globus has established barriers against competitors in a high-value product category.
The company's mention of separate litigation against Alphatec suggests a broader intellectual property enforcement strategy. This approach signals to other competitors that Globus intends to aggressively protect its innovation investments, potentially deterring future infringement and preserving market share.
For investors, this verdict validates Globus's R&D investments and demonstrates the company's ability to convert innovation into defensible market advantages. Patent litigation outcomes can significantly impact valuation in medical technology companies where intellectual property often constitutes the primary competitive moat.
AUDUBON, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globus in its patent infringement litigation against Life Spine, Inc.
The jury found that Life Spine’s Prolift family of implants infringed several claims of a valid Globus patent and awarded Globus both lost profits and reasonable royalty damages. The technology at issue involves expandable spinal fusion implants, an important advancement in patient care that can help improve outcomes in spinal surgery.
“We are pleased with the jury’s decision, which affirms the strength of our intellectual property and the groundbreaking innovation behind our expandable implant technologies,” said Keith Pfeil, President and Chief Executive Officer. “This verdict underscores Globus’s place as a leading innovator in the musculoskeletal field.”
In addition to the Life Spine case, Globus has a separate patent infringement litigation pending against Alphatec, Inc. involving expandable implant and retractor technology. The company stated that it remains committed to protecting its intellectual property while continuing to focus on innovation that benefits patients worldwide.
“We invest in research and development to bring transformative solutions to patients worldwide,” added Kelly Huller, Executive Vice President and General Counsel. “We will not hesitate to enforce our patent rights against those who attempt to use our technology without authorization.”
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive and Nevro businesses and our ability to successfully integrate and achieve anticipated synergies with the integration, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosure of Globus Medical contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Investor contact:
Brian Kearns
SVP, Corporate Development and Investor Relations
610-930-1800
investors@globusmedical.com
Media contact:
Moran Chavez
media@globusmedical.com
FAQ
What was the outcome of Globus Medical's patent lawsuit against Life Spine?
What technology was involved in GMED's patent infringement case?
Does Globus Medical have any other ongoing patent litigation cases?
Who is the current CEO of Globus Medical (GMED)?
What products were found to infringe on Globus Medical's patent?
